Drugs / ZANVIPIXANT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03547024 | Jun → Aug 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03437590 | Mar → Oct 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03151486 | May 2017 → Mar 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05328297 | Jun 2022 → May 2024 | bipolar disorder | Janssen Pharmaceutica N.V., Belgium | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZANVIPIXANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3914857 ↗ |
| Known as | JNJ-55308942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547024 ↗ |
| Modality | Small molecule | — CHEMBL3914857 ↗ |
| Route | Oral | “as an oral solution” NCT03151486 ↗ |